WO2024180511 - PROCESS FOR PREPARATION OF GLP-1 PEPTIDES HAVING CONTROLLED PARTICLE SIZE
National phase entry:
Publication Number
WO/2024/180511
Publication Date
06.09.2024
International Application No.
PCT/IB2024/051965
International Filing Date
29.02.2024
Title **
[English]
PROCESS FOR PREPARATION OF GLP-1 PEPTIDES HAVING CONTROLLED PARTICLE SIZE
[French]
PROCESSUS DE PRÉPARATION DE PEPTIDES GLP-1 AYANT UNE TAILLE DE PARTICULE CONTRÔLÉE
Applicants **
NOVETIDE LTD.
124 Dvora HaNevi'a St.
6944020 Tel Aviv, IL
Inventors
BAREL, Offir
41 Engel St.
4465146 Kfar Saba, IL
MASARWA, Abed
2 Karm AlJabali St.
P.O. Box 4407
Tayibe, IL
LAPIDO, Polina
3 Haim Hefer St.
Rishon Lezion, IL
Priority Data
63/449,375
02.03.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1850 | |
| EPO | Filing, Examination | 11613 | |
| Japan | Filing | 531 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 8435 |
Total: 23004 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure relates to processes for preparation of a peptide powder, and the preparation of peptide particles, for example a GLP-1 peptide such as Liraglutide, Dulaglutide, Exanetide, Lixisenatide and/or Semaglutide, and/or a salt thereof; particularly Liraglutide and Semaglutide and salts thereof; preferably Semaglutide and salts thereof, and more preferably Semaglutide. More specifically, the disclosure relates to a process comprising lyophilizing a solution comprising the peptide; and particle size reduction of the obtained lyophilizate. The disclosure further relates to GLP-1 peptides, particularly wherein the GLP-1 peptide is selected from Liraglutide, Dulaglutide, Exanetide, Lixisenatide and/or Semaglutide, and/or a salt thereof; preferably selected from Liraglutide and Semaglutide, and a salt thereof; and more preferably Semaglutide and a salt thereof, and most preferably Semaglutide, obtainable by said process and its use in medicine and cosmetic treatment.[French]
La présente divulgation concerne des processus de préparation d'une poudre peptidique, et la préparation de particules peptidiques, par exemple un peptide GLP-1 tel que le Liraglutide, le Dulaglutide, l'Exanetide, le Lixisenatide et/ou le Sémaglutide, et/ou leurs sels ; en particulier le Liraglutide et le Sémaglutide et leurs sels ; de préférence le Sémaglutide et ses sels, et de manière davantage préférée le Sémaglutide. Plus spécifiquement, la divulgation concerne un processus comprenant la lyophilisation d'une solution comprenant le peptide ; et la réduction de la taille des particules du lyophilisat obtenu. La divulgation concerne en outre des peptides GLP-1, le peptide GLP-1 étant en particulier choisi parmi le Liraglutide, le Dulaglutide, l'Exanetide, le Lixisenatide et/ou le Sémaglutide, et/ou leurs sels ; de préférence choisi parmi le Liraglutide et le Sémaglutide, et leurs sels ; et de manière davantage préférée le Sémaglutide et un sel de celui-ci, et de manière préférée entre toutes le Sémaglutide, pouvant être obtenu par ledit processus et son utilisation en médecine et dans un traitement cosmétique.